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Increased retinoic acid receptor b (RARb2) gene expression is a hallmark of cancer cell responsiveness to retinoid anticancer effects.
Moreover, low basal or induced RARb2 expression is a common feature of many human cancers, suggesting that RARb2 may act as a
tumour suppressor gene in the absence of supplemented retinoid. We have previously shown that low RARb2 expression is a feature
of advanced neuroblastoma. Here, we demonstrate that the ABC domain of the RARb2 protein alone was sufficient for the growth
inhibitory effects of RARb2 on neuroblastoma cells. ATP7A, the copper efflux pump, is a retinoid-responsive gene, was upregulated
by ectopic overexpression of RARb2. The ectopic overexpression of the RARb2 ABC domain was sufficient to induce ATP7A
expression, whereas, RARb2 siRNA blocked the induction of ATP7A expression in retinoid-treated neuroblastoma cells. Forced
downregulation of ATP7A reduced copper efflux and increased viability of retinoid-treated neuroblastoma cells. Copper
supplementation enhanced cell growth and reduced retinoid-responsiveness, whereas copper chelation reduced the viability and
proliferative capacity. Taken together, our data demonstrates ATP7A expression is regulated by retinoic acid receptor b and it has
effects on intracellular copper levels, revealing a link between the anticancer action of retinoids and copper metabolism.
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Retinoic acid receptors are members of the nuclear receptor super
family, which act as ligand-regulated trans-acting transcription
factors that bind to cis-acting DNA regulatory elements in the
promoter regions of target genes. Three RAR subtypes (RARa,
RARb, and RARg) originating from three distinct genes have been
identified (Mangelsdorf et al, 1990; Gronemeyer et al, 2004). RARs
belong to the steroid/thyroid hormone receptor super-family,
which share a common domain structure, denoted A-F. The C
region contains the DNA-binding domain, which is most
conserved among the different members of this family and
consists of two zinc fingers. The hormone-binding domain is
located in the E region and contains, besides the binding domain, a
dimerisation domain and a hormone-dependent transactivation
function (AF-2). The N-terminal part of the receptor (AB) also
contains an autonomous region involved in transactivation (AF-1),
which functions independently from the ligand, when coupled with
a heterologous DNA-binding domain. As the NH2-terminus is not
conserved among different receptors, they each may achieve this
function by distinct means (Evans, 1988; Leid et al, 1992).
Of particular interest is the RARb2 subtype, which regulates
essential pathways associated with the anti-tumour effects of
retinoids in epithelial cells. The RARb2 gene promoter contains a
retinoic acid response element (RARE) to which the liganded
RARa/RXRa heterodimer binds to induce RARb2 expression
(Alvarez et al, 2007). The expression of RARb2 is frequently
reduced in many neoplastic tissues when compared with their
normal cellular counterparts, including non-small cell lung cancer,
squamous cell carcinomas of the head and neck, breast cancer and
neuroblastoma (Cheung et al, 1996; Castillo et al, 1997; Picard
et al, 1999). The reactivation of silenced RARb2 upon induction of
RARa expression and concomitant retinoic acid treatment was
associated with a clinical response of oral leukoplakia (Lotan et al,
1995). In a clinical study where renal carcinoma patients were
treated with 13-cis-retinoic acid and interferon-a, the levels of
RARb2 increased in tumours that clinically responded to therapy
(Berg et al, 1999).
Copper plays an essential role in human physiology and is
indispensable for normal growth and development. Enzymes that
are involved in connective tissue formation, neurotransmitter
biosynthesis, iron transport and other essential physiological
processes require copper as a cofactor to mediate their reactions.
The transport and cellular metabolism of copper depends on a
series of membrane proteins and smaller soluble peptides that
comprise a functionally integrated system for maintaining cellular
copper homeostasis. Two membrane-bound copper-trans-
porting ATPase enzymes, ATP7A and ATP7B, can catalyse an
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sATP-dependent transfer of copper to intracellular compartments
or expel copper from the cell (Harris, 2000; El Meskini et al, 2005),
respectively. A truncated splice variant of ATP7A, termed NML45
(Nuclear Menkes Like) has also been described that encodes a
theoretical 11.2-kDa protein with one copper-binding site, and
may function as a nuclear copper chaperone (Reddy et al, 2000).
We have previously identified the copper metabolism gene
ATP7A as a retinoid-regulated gene in neuroblastoma cell lines
(Liu et al, 2005). In non-neuronal cells, ATP7A is responsive to
levels of intracellular copper, and is predominantly localised to the
trans-Golgi network when cytosolic copper levels are normal or
low. In the presence of excess copper, ATP7A functions in copper
excretion and a distinct pool of ATP7A is relocated to the plasma
membrane through cytoplasmic vesicles. It is rapidly recycled,
returning to the trans-Golgi network once cytoplasmic copper
levels are normal (La Fontaine et al, 1999; Lutsenko and Petris,
2003). In neurons ATP7A is developmentally regulated, being
initially expressed in cell bodies of developing neurons, with later
expression shifting to the extending axons and peaking just prior
to synaptogenesis (El Meskini et al, 2005). ATP7A has an
important function in neurodevelopment, and is involved in
axonal targeting, synaptogenesis and maturation of olfactory
sensory neurons (El Meskini et al, 2007).
In this study, we investigated the mechanisms of RARb2 in
mediating ligand-dependent and ligand-independent growth
inhibition functions by using in vitro models. Our results show a
previously unrecognised relationship between the RARb2 and
the anticancer effects of retinoids with ATP7A and intracellular
copper levels.
MATERIALS AND METHODS
Cell culture
The human neuroblastoma BE(2)-C and SH-SY5Y cell lines were
generously supplied by Dr J Biedler (Memorial Sloan-Kettering
Cancer Centre, NY, New York, USA). The human lung cancer H441
and SK-MES-1, human breast cancer MDA-MB-468, MDA-MB-231
and MCF7, and skin immortal keratinocyte HEK001 cells were
obtained from the American Type Culture Collection (Manassas,
VA, USA). The HEK001 was cultured in a specific keratinocyte
serum-free media as specified by the ATCC. All other cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with L-glutamine and 10% fetal calf serum. All-trans-retinoic acid
(aRA) was purchased from Sigma (NSW, Australia), was
solubilised in ethanol, stored at  701C, and used within 2 weeks
of solubilisation. Triethylenetetramine (TETA), a selective copper
chelator, was also purchased from Sigma.
Semi-quantitative competitive reverse
transcriptase–polymerase chain reaction
The competitive RT–PCR techniques have been described earlier
(Norris et al, 1997; Cheung et al, 2003), which involved determining
a ratio between the level of expression of a target gene and that of the
housekeeping gene b2-microglobulin (b2M) in total RNA samples.
Primers used for RT–PCR assays are as follows: human ATP7A
forward: 50-GGAATTCCCATAGCTGCTGG-30; human ATP7A
reverse: 50GTAAGTTGGTTTCCTGTAAA-30. This primer pair gen-
erated a 140-bp product extending from 4233 to 4373bp of published
ATP7A sequence. NLM45 forward: 50-CTGAGCATCAGAAAGAGAC
CA-30; NML45 reverse: 50-ATCTGCTGCTCAATGGTCCA-30. This
primer pair generated a 146-bp product extending from 122 to
146bp of published NML45 sequence. Human RARb2 forward:
50-CTACACTGCGAGTCCGTCTT-30. Human RARb2 reverse:
50-CAGAGCTGGTGCTCTGTGTT-30. This primer pair generated a
131-bp product extending from 375 to 506bp of published RARb2
sequence.
Quantitative real-time PCR
cDNA for real-time PCR was synthesized from total RNA using a
Superscript III synthesis kit and Oligo(dT)20 primer (Invitrogen,
Vic, Australia), according to manufacturer instructions. The cDNA
(40ng) was amplified in 25ml reactions using a Power SYBR Green
PCR master mix (Applied Biosystems, Melbourne, VIC, Australia)
and 100ng each of forward and reverse primers on an ABI PRISM
7500 Sequence Detection System (Applied Biosystems). The cycle
threshold (Ct), fixed in the exponential phase of the PCR, was used
to determine gene expression relative to a calibrator. For each
sample, the Ct value of the target gene was normalised to the
endogenous control gene b2M. Relative gene expression was calculated
with the 2 DDCt method (Livak and Schmittgen, 2001). Real-time PCR
primer sequences are listed as follows: Human ATP7A forward: 50-TG
GCAAGGCAGAAGTAAGGTATAA-30; Human ATP7A Reverse: 50-ACGT
CATTCCCCTCACAACAAG-30; Human RARb2 forward: 50-TGAAAA
TCACAGATCTCCGTAGCA-30; Human RARb2 reverse: 50-CCAG
GAATTTCCATTTTCAAGGT-30; Human b2M forward: 50ACTGG
TCTTTCTATCTCTTGTACTACACTGA-30; Human b2M reverse:
50 TGATGCTGCTTACATGTCTCGAT-30.
Plasmid construction
The full-length human cDNA for RARb2 (kindly provided by
Professor P Chambon, INSERM, Strasbourg, France) was cloned
into the PvuII multi-cloning site of the pMEP4 episomal Epstein–
Barr virus-based expression vector (kindly provided by Dr M
Tykocinski, Case Western University, Cleveland, OH, USA)
(Cheung et al, 1996). We designed mutant RARb2 cDNAs, which
were deleted for either the ligand-independent AF-1 transactivat-
ing domain (A-B) and the DNA-binding domain (C) – DDEF, or
the ligand-binding domain (E-F) – DABC and DAB (Figure 1B).
We used a PCR-based strategy to amplify separate regions of the
RARb cDNA by using pREP/RARb plasmid DNA as template
(Cheung et al, 1996). The mutant RARb cDNAs were subcloned
into the multi-cloning site (Hind III and Cla I) of a pTet-splice
Myc/His vector (Invitrogen). Plasmid pTet-tTAK (Invitrogen) was
stably transfected into BE(2)-C cells to establish stable BE(2)-C
pTet-tTAK clones. The pTet-splice vectors which contained
the RARb mutants were transiently transfected into BE(2)-C
(pTet-tTAK clones) and BrdU incorporation was performed in
medium without tetracycline.
The oligonucleotides used for the PCR assay of RARb deletion
mutants were as follows: Forward primer for DDEF: 50-AGTC-
GAGGTATCGATGTTTGACTGTATGGATGT-30; Reverse primer
for DDEF: 50-AGCAGAAAGCTTGGACATTCCCACTTCAAAGC-30;
Forward primer for DAB: 50-AGTCGAGGTATCGATGGCTTCGT
CTGCCA-30; Forward primer for DABC: 50-AGTCGAGGTATCG
ATGAAAGAATCTGTCAGGAA-30; Reverse primer for both DAB
and DABC: 50-AGCAGAAAGCTTAAGGGTTCATGTCCTTCAGA-30.
Assays of neurite formation and viability assays
Neurite extension of neuroblastoma cells BE(2)-C was determined
after 7 days of continuous exposure to 10mM aRA and 30 or 100mM
copper. Cells were scored as positive for neurite outgrowth if the
neuritic process was longer than the cell body. The percentage of
positive cells was counted within each high-powered field, with a
total of 300 cells counted in an average of five fields. Each
experiment was performed in duplicate on three separate
occasions. Cell viability was assessed using Alamar Blue reagent
as described earlier (Haber et al, 1999).
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ssiRNA-transient transfection
SH-SY5Y and BE(2)-C cells at approximately 50% confluence were
transfected with 30nM ATP7A siRNA (Smart Pool: Dharmacon,
Chicago, IL, USA) or 10nM RARb2 siRNA and 10nM siGENOME
non-targeting siRNA as control siRNA (Dharmacon) using
Lipofectamine 2000 (Invitrogen) reagent according to the manu-
facturer’s protocols. Following transfection, cells were incubated
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Figure 1 Tumour-suppressive activity of RARb2 in neuroblastoma tumour cells. (A) BE(2)-C and SH-SY5Y cells were transfected with control siRNA or
RARb2-specific siRNA, followed by treatment with 10mM aRA for 48h and incubation with BrdU for the last 2h. In the upper panel, BrdU incorporation was
measured as OD units of absorbance. In the lower panel, RT–PCR experiments show the knock-down of RARb2 mRNA expression level by RARb2-specific
siRNA. (B) Schematic representations of RARb2 full-length and deletion mutant constructs used in this study. In the right panel, expression of RARb2 full
length and deletion mutants in BE(2)-C pTet-tTAK cells were analysed by western blot by using anti-Myc-tag antibody. The lysates of the cells transiently
transfected with empty vector (EV, lane 1), RARb2 full-length (lane 2, 50KDa), DDEF (lane 3, 16kDa), DABC (lane 4, 34kDa) and DAB (lane 5, 41kDa)
constructs were used in this study. (C) Proliferation of BE-tet-75 cells transiently transfected with RARb2 full-length and deletion mutant constructs in the
absence of added retinoid. *Po0.05 and **Po0.01 indicate a statistically significant difference compared with untreated control (Figure 1A) or empty
vector control (Figure 1C). Error bars indicate s.e.m.
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sovernight in normal media, and then treated with 1mM aRA or
solvent control. Cells were harvested and RNA was extracted 48 or
72h later. Transfection efficiency and its effect on target gene
expression, was assessed by competitive RT–PCR.
Western blot
Cells were harvested in the presence of protease inhibitors by
direct lyses in the culture vessel with lyses buffer (RIPA: 100mM
NaCl, 0.5% Sodium deoxycholate, 50mM Tris-Cl, 0.1% SDS, 1%
NP-40) and then transferred to eppendorf tubes. Soluble proteins
were analysed by SDS–PAGE as published earlier (Cheung et al,
2003). Membranes were probed with chicken IgY anti-ATP7A
which is specific for full-length ATP7A (no. ab13995: Abcam,
Cambridge, UK), at a dilution of 1/1000 overnight at 41C.
Membranes were then incubated for 1h at room temperature with
a secondary antibody, HRP conjugated rabbit anti-chicken (no.
ab6753: Abcam) at a dilution of 1/2000. Membranes were
re-probed with an anti-b-Actin antibody (Pierce, IL, USA) as a
loading control, according to methods described earlier (Cheung
et al, 2003). Relative protein expression was determined by
standardising target protein bands against b-Actin using Image-
Quant software (Amersham, NSW, Australia).
Mouse monoclonal antibody anti-Myc-Tag (9B11) was
purchased from Cell Signalling Technology Inc. (MA, USA) for
detecting RARb2 full-length and its mutant’s expression in BE(2)-C
cells. Anti-Myc-Tag antibody for RARb2 deletion mutants
immunoblot was used at a 1:1000 dilution in 0.5% defatted milk
in a TBST buffer. Rabbit polyclonal Actin antibody (Sigma, St
Louis, MO, USA) was used at a 1:2000 dilution to normalise for
differences in loading. Subsequently, membranes were incubated
with horseradish peroxidise, anti-mouse or anti-rabbit secondary
antibody (Pierce Biotechnology Inc., IL, USA), which was used at a
1:5000 dilution. Chemiluminescent detection was performed using
the SuperSignal western blotting kit (Pierce Biotechnology,
Rockford, IL, USA), according to the manufacturer’s instructions.
Accumulation of copper 64
The accumulation of radioactive copper was analysed using
standard techniques (Richardson and Baker, 1990; Arredondo
et al, 2006). Briefly, BE(2)-C and SH-SY5Y cells in 35mm wells
were incubated for 2h at 371C with 10mCiml
 16 4 Cu, in the form of
CuCl2 (ARI, Lucas Heights, NSW, Australia) in DMEM supple-
mented with 10% fetal calf serum. The cells were then placed on a
tray of ice and washed four times with ice-cold PBS to remove any
non-specifically bound
64Cu. The internalised and membrane-
bound
64Cu were incubated with 1ml trypsin. After this
incubation, the cells were then removed from the wells and
transferred to g-counting tubes. Radioactivity was measured using
a g-counter (Wallac Wizard 3; Turku, Finland). Control experi-
ments in previous investigations have found that this technique
is valid for measuring membrane-bound and internalised
radioactivity (Karin and Mintz, 1981).
Efflux of copper 64
The release of
64Cu by pre-labelled cells was examined using
standard procedures (Richardson and Baker, 1991; Food et al,
2002). Cells in 35mm wells were labelled with 10mCiml
 16 4 Cu in
DMEM containing 10% fetal calf serum for 2h at 371C. The 35mm
plates were subsequently placed on a tray of ice and washed four
times with ice-cold PBS. The cells were then re-incubated with
warm DMEM for incubation periods from 1, 2.5 or 4h to allow
cells to efflux copper into the medium. The overlying medium was
then removed and placed into g-counting tubes. The cells were
removed from the 35mm well plates, either by trypsinisation or
direct lyses, and transferred to a separate set of g-counting tubes.
Total
64Cu accumulated by cells prior to efflux was determined for
each well by adding CPM for
64Cu effluxed and
64Cu retained in the
cells.
64Cu effluxed was expressed as a percentage of total
64Cu
accumulated. Estimates of
64Cu accumulated per cell was obtained
by standardising total
64Cu accumulated against estimated cell
viability (OD).
RESULTS
Growth and tumour-suppressive activity of RARb2 in
neuroblastoma cells
We first determined the effect of RARb2 expression on the
proliferative capacity of neuroblastoma cells in the presence and
absence of 10mM all-trans-retinoic acid (aRA). We performed a
BrdU incorporation assay in two human neuroblastoma cell lines
(BE(2)-C and SH-SY5Y) transiently transfected with a siRNA
specific for RARb2, followed by 48h of aRA treatment. RARb2
expression was reduced by 60% when compared to control siRNA
as measured by gel densitometry in both cell lines (Figure 1A). Cell
proliferation was significantly increased, with or without aRA, in
both neuroblastoma cell lines following RARb2 knockdown,
compared with cells transfected with a non-specific siRNA control
(Figure 1A).
To understand the relationship between RARb2 protein
structure and its effects on cell proliferation in the absence of
additional retinoid, we made a series of RARb2 deletion mutants in
a tetracycline-inducible expression (Tet-off) vector with a Myc
oligopeptide tag (Figure 1B). The RARb2 deletion mutant proteins
were transiently expressed in BE(2)-C cells, and, an anti-Myc
epitope antibody identified the expression of all mutant proteins
expected. Cell proliferation was measured by BrdU incorporation
after cells were grown in culture medium without doxycycline for
72h. Overexpression of the full length RARb2 resulted in
significantly decreased cell proliferation compared with empty
vector. Most importantly, overexpression of the ABC domain
(DDEF) of the RARb2 protein alone was sufficient for the growth
inhibitory effects of RARb2 in BE(2)-C cells. In contrast,
overexpression of CDEF (DAB) and DEF (DABC) domains of
RARb2 did not decrease cell proliferation (Figure 1C).
RARb regulates the expression of ATP7A in neuroblastoma
cells
We have previously identified the copper efflux pump protein,
ATP7A, as a retinoid-regulated gene using a cDNA microarray
analysis of retinoid-treated neuroblastoma cells (Liu et al, 2005).
Here, we examined the hypotheses that RARb2 may regulate
ATP7A, and, that ATP7A may be responsible for the growth
suppressive effects of RARb2 in neuroblastoma cells. We found
that transcription of both the full-length ATP7A, and the ATP7A
splice variant, NML45, were markedly induced by aRA in BE(2)-C
and SH-SY5Y cells after treatment with 10mM aRA for 7 days
(Figure 2A). Consistent with these findings, ATP7A protein
expression was also induced by aRA after 3 days of treatment
(Figure 2B). Retinoid-induced upregulation of ATP7A appeared to
be specific for neuroblastoma cells, as we could not demonstrate
an increase in ATP7A mRNA expression in skin, lung or breast
cancer cells following retinoid treatment (Figure 2C). We have also
observed that the aRA decreases ATP7A mRNA expression in
oestrogen-receptor positive MCF7 cells, but not in MDA-MB-234
and MDA-MB-468 breast cancer cells.
We have previously characterised two clonally-derived BE(2)-C
cell lines stably overexpressing RARb2, which exhibited growth
suppression in the absence of added retinoid (Cheung et al, 1998).
Both RARb2 clones demonstrated increased ATP7A and NML45
expression, when compared with empty vector transfectants.
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sInterestingly, the levels of the splice variant NML45 does not
correlate with the levels of RARb2 in two different RARb2 clones
(Figure 3A). We next transiently transfected BE(2)-C cells with
RARb2-specific siRNA, treated the cells with 10mM aRA for 48h,
and examined RARb2 and ATP7A expression. Consistent with our
previous findings, expression of retinoid-induced RARb2 and
ATP7A was coordinately decreased, compared with retinoid-
untreated samples (Figure 3B). Additionally, transiently expressing
the RARb2 full-length and the DDEF deletion mutant, significantly
increased ATP7A expression (Figure 3B). Thus, we found a close
relationship between RARb2 and ATP7A expression levels, and
growth inhibition in several different model systems, supporting
the notion that ATP7A may mediate the retinoid ligand-
dependent, and -independent, actions of RARb2.
The retinoid anti-cancer effect is mediated by effects on
ATP7A and intracellular copper
We next examined the hypothesis that ATP7A mediates the effects
of RARb2 on neuroblastoma cells by its effects on intracellular
copper metabolism. We measured copper efflux in neuroblastoma
cells (BE(2)-C and SH-SY5Y) which were pre-treated with 10mM
aRA over a time course of 8 days, then loaded with radioactive
64Cu. After
64Cu loading, cells were washed, then incubated in
normal growth media to allow copper efflux over a short 4h time
course. In both cell lines there was a higher copper efflux in cells
pre-treated with aRA at 4h (Figure 4A). As the retinoid treatment
affects the cell number at the end of the growth period,
64Cu
uptake was standardised against cell viability, as assessed by the
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Figure 2 ATP7A is induced by retinoid in neuroblastoma tumour cells. (A) Competitive RT–PCR analysis of cDNA samples from cultured
neuroblastoma cells treated with 10mM aRA, or a solvent control, for up to 7 days. Abundance of ATP7A transcripts (full length and NML45) present in
SH-SY5Y and BE(2)-C cDNA samples relative to b2M neuroblastoma cell lines. (B) Western blot analysis of ATP7A protein expression from cultured
neuroblastoma cells treated with 10mM aRA, or a solvent control, for up to 7 days. Actin gene was used as a loading control. (C) Competitive RT–PCR
analysis of ATP7A mRNA expression in cDNA samples from cultured cancer cells treated for 7 days with 10mM aRA, or a solvent control.
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sAlamar Blue assay (Figure 4B). Retinoid treatment resulted in a
marked decrease in
64Cu accumulation in both SH-SY5Y and
BE(2)-C cells.
To directly examine the role of ATP7A in modulating copper
efflux in neuroblastoma cells, we used siRNA specific for ATP7A.
Transient transfection of SH-SY5Y cells with an ATP7A siRNA lead
to a 36% þ/  0.018 s.e.m. reduction in ATP7A expression and a
27% þ/  0.015 s.e.m. reduction in the rate of copper efflux in
retinoid-untreated cells, suggesting that the rate of copper efflux
in this cell line was dependent on ATP7A, and, was proportional to
the level of ATP7A expression (Figure 4C). There was no effect on
BE(2)-C cells. The ATP7A knock-down did not alter the copper
accumulation in untreated SH-SY5Y or BE(2)-C cells. We next
examined the effect of inhibiting ATP7A expression on the
viability of retinoid-treated neuroblastoma cells. Owing to the
combined toxicity of siRNA and retinoid treatment, the experi-
ment was limited to 24h retinoid treatment, and a lower retinoid
concentration of 1mM aRA. In both SH-SY5Y and BE(2)-C cells, a
reduction in ATP7A expression of approximately 30% correlated
with an increase in cell viability in the Alamar Blue assay,
compared with a non-specific siRNA control (Figure 4D).
We next examined the effects of copper supplementation on the
retinoid responses of neuroblastoma cells. BE(2)-C and SH-SY5Y
cells were grown according to standard techniques, in the absence
of added retinoid and supplemented with 0, 30, 100 and 300mM
copper treatment for 48h. Cell proliferation was assessed using the
BrdU incorporation assay. Supplementing BE(2)-C with 30, 100
and 300mM CuCl2 significantly increased cell proliferation
(Figure 5A). None of the concentrations tested increased the
proliferation of SH-SY5Y cells (data not shown). BE(2)-C and
SH-SY5Y cells were then grown for 7 days with 10mM aRA, in the
presence or absence of 30 and 100mM CuCl2. After 7 days,
differentiation was assessed by neurite count. Added CuCl2
significantly reduced neurite formation in BE(2)-C cells over the
7 day retinoid treatment (Figure 5A). Moreover, the copper
chelator, Triethylenetetramine (TETA), reduced the viability and
proliferative capacity of BE(2)-C cells compared to cells grown
without TETA. The effect was completely abrogated when TETA
was added with equimolar CuCL2 (Figure 5B). Copper supple-
mentation had no observable effect on retinoid-induced
differentiation of SH-SY5Y cells. In both cell lines copper
supplementation did not affect the neurite count of cells grown
in the absence of the added retinoid (data not shown).
Lastly, we investigated whether a combination of retinoid and
copper chelator could increase their anti-cancer activity. Both
BE(2)-C and SH-SY5Y neuroblastoma cells were treated with a
single agent or a combination of aRA (1mM) and TETA (60mM) for
72h. The effect of the copper chelator by itself had only a minor
growth inhibitory effect on SH-SY5Y and BE(2)-C cell lines,
whereas the combination treatment of retinoid and copper
chelator had a marked effect on cell viability and proliferation
(Figure 6).
DISCUSSION
A therapeutic role for retinoids in several human cancer types,
including neuroblastoma, is well established. However, retinoids
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sare not completely effective anti-cancer agents when used alone;
thus, a better understanding of their mechanism of action will lead
to more evidence-based retinoid combination therapies. In this
study we have demonstrated that RARb2 has a strong, retinoid-
dependent and -independent, anti-proliferative effects on neuro-
blastoma cells. Furthermore, we have, for the first time, identified
a link between the retinoid anti-cancer signal and intracellular
copper levels, which has important implications for the
understanding of the tumorigenic process and therapy of
neuroblastoma.
In human neuroblastoma cells, knocking down RARb2 expres-
sion resulted in a clear increase in cell proliferation, regardless of
whether or not exogenous retinoid was added. Conversely,
overexpression of RARb resulted in a strong decrease in cell
proliferation. The RARb2 anti-proliferative effect required only the
ABC domain (AF1 and DNA-binding domains), and not
the retinoid-binding domain or receptor dimerisation interface.
This result strongly suggests that RARb2 has both retinoid-
dependent and -independent anti-cancer functions.
In a previous study using the cDNA microarray, we found that
the copper transporter ATP7A was strongly upregulated in
neuroblastoma cells in response to retinoid (Liu et al, 2005).
In this study, we found that ATP7A protein expression is
upregulated in neuroblastoma cells after retinoid treatment. As
retinoid treatment did not result in similar upregulation of ATP7A
expression in the non-neuronal cell lines, which tested, we suggest
that retinoid regulation of ATP7A is tissue type-dependent and
may be specific to neuronal cells. We have also shown that ATP7A
upregulation can be achieved by ectopic expression of full-length
RARb2 or the RARb2 ABC domain in the absence of added
retinoid. Our data supports the notion that RARb2, directly or
indirectly regulates ATP7A expression in a retinoid-dependent and
-independent manner.
During neuronal development, ATP7A expression over time is
precisely regulated, and varies according to cell type (Linz and
Lutsenko, 2007). Studies of the mouse brain show that ATP7A
expression is most abundant in the early postnatal period and
decreases from birth to adulthood (Niciu et al, 2006). The
mechanism by which RARb regulates ATP7A expression is
unknown. As there are no known RARE in the ATP7A promoter
region, it is likely that RARb regulates ATP7A expression level
indirectly. Previous studies focused on the role of ATP7A in
Menke’s disease, have shown that ATP7A expression and copper
plays an important role in neural differentiation and neuritogen-
esis (El Meskini et al, 2005, 2007; Birkaya and Aletta, 2005). We
found an increase in cell viability when ATP7A expression was
knocked down in neuroblastoma cells (Liu et al, 2005). The
significant correlation between ATP7A and RARb expression
suggests that ATP7A may contribute to the RARb anti-cancer
therapeutic effect.
The role of copper in biological phenomena that involve signal
transduction is poorly understood. A cellular model of neuronal
differentiation has been utilised to examine the requirement for
copper during nerve growth factor (NGF) signal transduction that
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sleads to neurite outgrowth (Birkaya and Aletta, 2005). NGF
increases cellular copper content within 3 days, whereas copper
chelators reduce the effects of NGF on neurite outgrowth and
copper accumulation (Birkaya and Aletta, 2005). Our data
supports a model of malignant neural cells requiring higher
intracellular copper levels for viability, and that retinoid-induced
neuritic differentiation of neuroblastoma cells causes intracellular
copper depletion. In non-neuronal cells ATP7A regulates copper
homeostasis by translocating copper from the trans-Golgi network
to the plasma membrane, in response to an increased copper load.
In Menkes disease a defect in the ATP7A protein leads to a reduced
transport of copper from the intestine into the circulation and
central nervous system, as well as reduced transport of copper into
the Golgi apparatus. In our studies, a significant increase in copper
efflux, and decrease in copper uptake occurred over 8 days of
retinoid treatment. Thus, reduction in cellular copper levels
directly contributes to the retinoid therapeutic effect.
In summary, our results indicate that ATP7A is an important
component of the RARb anticancer effect. Most importantly,
copper chelators reduce viability and proliferation of neuroblas-
toma cells. ATP7A and copper are novel potential drug targets that
may be exploited in the treatment of neuroblastoma.
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